No data to show
XMAD
ORY
Market cap177mUSD
Apr 11, Last price
2.72EUR
1D
1.87%
1Q
78.95%
Jan 2017
-37.46%
IPO
-32.22%
Name
Oryzon Genomics SA
Chart & Performance
P/E
—
P/S
11.04
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.42%
Rev. gr., 5y
29.46%
Revenues
7m
-48.15%
Net income
-4m
L+9.32%
CFO
-6m
L+889.58%
Earnings
May 05, 2025
Profile
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 7,359 -48.15% | 14,192 | ||||
Cost of revenue | 302 | 6,480 | 2,382 | |||
Unusual Expense (Income) | ||||||
NOPBT | 7,057 | 7,712 | (2,382) | |||
NOPBT Margin | 95.89% | 54.34% | ||||
Operating Taxes | 1,906 | (2,751) | (2,325) | |||
Tax Rate | 27.01% | |||||
NOPAT | 5,151 | 10,463 | (57) | |||
Net income | (3,665) 9.32% | (3,353) -20.76% | (4,231) -9.72% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (1,800) | |||||
BB yield | 1.57% | |||||
| Debt | ||||||
Debt current | 8,759 | 11,939 | 10,380 | |||
Long-term debt | 7,512 | 3,529 | 7,160 | |||
Deferred revenue | ||||||
Other long-term liabilities | 2,481 | 5,260 | 3,285 | |||
Net debt | 10,652 | 3,212 | (3,777) | |||
| Cash flow | ||||||
Cash from operating activities | (5,690) | (575) | (1,848) | |||
CAPEX | (14,271) | |||||
Cash from investing activities | (7,811) | (14,504) | (14,271) | |||
Cash from financing activities | 6,871 | 6,021 | 8,710 | |||
FCF | 5,127 | 10,593 | 14 | |||
| Balance | ||||||
Cash | 5,619 | 12,257 | 21,317 | |||
Long term investments | ||||||
Excess cash | 5,251 | 11,547 | 21,317 | |||
Stockholders' equity | (11,642) | (12,615) | (9,540) | |||
Invested Capital | 117,379 | 115,040 | 102,629 | |||
ROIC | 4.43% | 9.61% | ||||
ROCE | 6.67% | 7.53% | ||||
| EV | ||||||
Common stock shares outstanding | 64,371 | 60,879 | 56,042 | |||
Price | 1.43 -24.05% | 1.89 -23.87% | 2.48 -8.15% | |||
Market cap | 92,308 -19.69% | 114,940 -17.30% | 138,985 -2.44% | |||
EV | 102,960 | 118,152 | 135,208 | |||
EBITDA | 7,204 | 7,865 | (2,216) | |||
EV/EBITDA | 14.29 | 15.02 | ||||
Interest | 1,894 | 1,119 | ||||
Interest/NOPBT | 24.55% | |||||